Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in <i>BRCA1</i>, <i>BRCA2</i>, or <i>PALB2</i>Kim A. Reiss, Susan M. Domchek, Katherine L. Nathanson et al.|Journal of Clinical Oncology|2021Cited by 238
Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trialKim A. Reiss, Robert H. Vonderheide, Rosemarie Mick et al.|The Lancet Oncology|2022Cited by 137
Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and NeckRobert L. Ferris, Ezra E.W. Cohen, Nabil F. Saba et al.|JAMA Oncology|2018Cited by 111
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline <i>BRCA</i> or <i>PALB2</i> MutationShun Yu, Kim A. Reiss, Parul Agarwal et al.|JCO Precision Oncology|2019Cited by 37
Phase I Trial of Regorafenib, Hydroxychloroquine, and Entinostat in Metastatic Colorectal CancerThomas B. Karasic, Peter J. O’Dwyer, Timothy J. Brown et al.|The Oncologist|2022Cited by 33